|
Forecast
Period
|
2025-2029
|
|
Market
Size (2023)
|
USD
4.76 Billion
|
|
CAGR
(2024-2029)
|
6.25%
|
|
Fastest
Growing Segment
|
Colorectal Cancer
|
|
Largest
Market
|
North
America
|
|
Market
Size (2029)
|
USD
6.77 Billion
|
Market Overview
Global Immuno Oncology Assays Market was valued at USD
4.76 Billion in 2023 and is anticipated to project steady growth in the
forecast period with a CAGR of 6.25% through 2029. The global immuno-oncology
assays market is witnessing substantial growth, driven by advancements in
cancer immunotherapy and an increased focus on personalized medicine.
Immuno-oncology assays play a crucial role in the development, monitoring, and
optimization of immunotherapies by assessing the immune system’s response to
cancer.
The growing incidence of cancer globally is a
significant driver of the immuno-oncology assays market. According to the World
Health Organization (WHO), cancer is the second leading cause of death
worldwide, with millions of new cases reported each year. This increase in
cancer cases has accelerated the demand for innovative treatment options,
including immunotherapy, which harnesses the body's immune system to target and
destroy cancer cells. Immuno-oncology assays are essential in evaluating the
efficacy of these therapies, leading to market growth.
Immunotherapy has emerged as a transformative
approach in cancer treatment, with therapies such as checkpoint inhibitors,
CAR-T cell therapy, and cancer vaccines showing significant promise. These
treatments require precise and detailed assessments to optimize their
effectiveness and monitor patient responses. Immuno-oncology assays, which
include biomarkers and functional assays, are critical in this process. They
help identify suitable patients for specific therapies, predict treatment
responses, and monitor disease progression, thereby driving demand for these
assays.
Technological advancements are playing a pivotal
role in the expansion of the immuno-oncology assays market. Innovations such as
next-generation sequencing (NGS), high-throughput screening, and multiplex
assays have enhanced the ability to analyze complex biological samples with
high precision and efficiency. These technologies facilitate the identification
of novel biomarkers and provide insights into the immune landscape of tumors,
supporting the development of targeted and personalized immunotherapies.
The global immuno-oncology assays market is poised
for substantial growth, driven by rising cancer incidence, advancements in
immunotherapy, and technological innovations. While challenges such as high
costs and regulatory hurdles exist, opportunities in emerging markets and
ongoing research and development present a promising future for the sector. As
the demand for personalized and effective cancer treatments continues to rise,
immuno-oncology assays will play a critical role in advancing cancer care and
improving patient outcomes.
Key Market Drivers
Rising Incidence of Cancer
The global immuno-oncology assays market is
experiencing significant growth, largely driven by the escalating incidence of
cancer worldwide. As cancer remains a leading cause of morbidity and mortality,
there is an increasing demand for advanced diagnostic and therapeutic tools to
manage and treat this complex disease. Immuno-oncology assays, which are
critical in evaluating the immune response to cancer, play a pivotal role in
the development and optimization of immunotherapies.
The rising prevalence of cancer is attributed to
factors such as aging populations, lifestyle changes, environmental exposures,
and improved diagnostic capabilities. This surge in cancer cases has
intensified the need for effective diagnostic and treatment solutions,
including immuno-oncology assays.
According to the World Health Organization (WHO)
statistics from 2022, cancer remains a leading cause of death globally,
accounting for nearly 10 million fatalities in 2020, or roughly one in six
deaths. The most prevalent types of cancer include breast, lung, colorectal,
and prostate cancers. Approximately one-third of cancer deaths are attributed
to risk factors such as tobacco use, high body mass index, alcohol consumption,
inadequate fruit and vegetable intake, and insufficient physical activity.
Additionally, air pollution is a significant risk factor for lung cancer.
Infections that cause cancer, such as human papillomavirus (HPV) and hepatitis,
contribute to around 30% of cancer cases in low- and lower-middle-income
countries. Many cancers can be effectively treated and potentially cured if
detected early and managed properly.
The increasing burden of cancer is placing
substantial pressure on healthcare systems around the world. Governments and
healthcare providers are seeking innovative approaches to improve cancer
management and patient outcomes. Immuno-oncology assays are essential in this
regard, as they help in the identification of biomarkers, assessment of immune
responses, and monitoring of treatment efficacy, thereby supporting more
personalized and effective cancer care.
Immunotherapy has emerged as a groundbreaking
approach in cancer treatment, harnessing the body's immune system to target and
destroy cancer cells. This modality includes various therapies such as
checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines. The effectiveness
of these treatments relies heavily on accurate and comprehensive assessments
provided by immuno-oncology assays. These assays help in identifying suitable
candidates for specific therapies, predicting treatment responses, and
monitoring disease progression, thus driving the demand for advanced assay
technologies.
Immuno-oncology assays are crucial in the discovery
and validation of biomarkers that are predictive of treatment responses or
disease progression. For example, assays that measure the expression of PD-L1,
a protein associated with immune checkpoint inhibition, are used to identify
patients who are likely to benefit from checkpoint inhibitor therapies. The
increasing focus on personalized medicine and targeted therapies is driving the
demand for assays that can accurately identify relevant biomarkers and guide
treatment decisions.
Advancements in technologies such as
next-generation sequencing (NGS) are enhancing the capabilities of
immuno-oncology assays. NGS allows for comprehensive genomic profiling of
tumors, identifying genetic mutations and alterations that can influence cancer
progression and treatment responses. This technology provides valuable insights
for developing targeted immunotherapies and optimizing patient management strategies.
Multiplex assays and high-throughput screening
technologies enable the simultaneous measurement of multiple biomarkers and
immune responses. These innovations improve the efficiency and accuracy of
assessments, supporting the development of more effective immunotherapies and
driving market growth.
The rising incidence of cancer is a significant
driver of the global immuno-oncology assays market. As cancer prevalence
continues to increase, the demand for advanced diagnostic and therapeutic
tools, including immuno-oncology assays, is growing. These assays play a
critical role in advancing immunotherapy, identifying biomarkers, and
optimizing cancer treatment. While challenges such as high costs and regulatory
hurdles exist, opportunities in emerging markets and ongoing technological
innovations offer a promising outlook for the market. As the global fight
against cancer intensifies, immuno-oncology assays will remain at the forefront
of efforts to improve patient outcomes and advance cancer care.
Advancements in Immunotherapy
The global immuno-oncology assays market is
experiencing robust growth, significantly driven by advancements in
immunotherapy. As the field of immunotherapy evolves, the demand for
sophisticated assays that can effectively support and optimize these treatments
has surged.
Immunotherapy has revolutionized cancer treatment
by harnessing the body's immune system to target and destroy cancer cells.
Innovations such as checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines
have demonstrated remarkable efficacy in treating various types of cancer.
These advancements have not only expanded the scope of immunotherapy but also
underscored the need for advanced diagnostic tools to ensure the optimal use of
these therapies.
In March 2024, Researchers at the Wyss Institute at
Harvard University and Harvard’s John A. Paulson School of Engineering and
Applied Sciences (SEAS) have made significant strides in neutrophil therapies.
While neutrophils have been employed for over 40 years to bolster the immune
systems of cancer patients undergoing chemotherapy, utilizing neutrophils to
directly target cancer cells represents a novel approach. The research team has
innovatively attached disc-shaped micropatches to neutrophils, allowing these
cells to sustain their anti-tumor (N1) state. This technique has demonstrated
promising results in preclinical studies involving mice.
Checkpoint inhibitors, such as pembrolizumab
(Keytruda) and nivolumab (Opdivo), work by blocking proteins that inhibit the
immune system’s ability to attack cancer cells. These therapies have shown
substantial promise in treating cancers like melanoma, lung cancer, and bladder
cancer. The success of checkpoint inhibitors has driven the need for assays
that can identify patients most likely to benefit from these treatments by
assessing biomarker expression levels, such as PD-L1.
Chimeric Antigen Receptor T-cell (CAR-T) therapy
involves modifying a patient’s T-cells to recognize and attack cancer cells.
This personalized approach has been effective in treating hematologic
malignancies. However, CAR-T therapies require rigorous monitoring to manage
potential side effects and assess treatment efficacy, driving demand for
specialized assays that can track CAR-T cell activity and monitor patient
responses.
Therapeutic cancer vaccines aim to stimulate the
immune system to target cancer cells specifically. These vaccines are designed
to enhance the immune response against tumor-associated antigens. The
development of cancer vaccines necessitates assays that can evaluate immune
responses and predict patient outcomes, supporting the ongoing advancement of
these therapies.
Oncolytic virus therapy uses genetically modified
viruses to selectively infect and kill cancer cells while sparing normal cells.
This novel approach requires advanced assays to assess viral activity, immune
response, and the impact on tumor progression, highlighting the need for
innovative diagnostic tools.
As immunotherapy continues to advance, there is an
increasing need for precise diagnostic tools to identify suitable candidates
and monitor treatment responses. Immuno-oncology assays are crucial for
evaluating biomarkers, assessing immune responses, and guiding treatment
decisions. The integration of these assays into clinical practice is essential
for maximizing the benefits of immunotherapy.
The success of immunotherapies has led to the
development of companion diagnostics that help determine patient eligibility
for specific treatments. These companion assays are designed to identify
biomarkers associated with therapeutic response, ensuring that patients receive
the most appropriate and effective therapies.
Regulatory agencies are increasingly supporting the
use of immuno-oncology assays as integral components of immunotherapy
treatments. Approvals and guidelines for these assays facilitate their adoption
in clinical settings, further driving market growth.
The continuous advancements in immunotherapy create
opportunities for ongoing research and development in assay technologies.
Innovations in assay platforms, such as high-throughput screening and
next-generation sequencing, are expanding the capabilities of immuno-oncology
assays and supporting the development of new therapeutic approaches.
Download Free Sample Report
Key Market Challenges
High Development and Validation Costs
The global immuno-oncology assays market is
experiencing significant growth, driven by the increasing adoption of
immunotherapy and the need for precise diagnostic tools. However, one of the
most pressing challenges facing this market is the high development and
validation costs associated with these assays. These costs impact not only the
pace of innovation but also the accessibility and affordability of advanced
diagnostic solutions.
The development of immuno-oncology assays involves
a multi-faceted process that is both intricate and resource-intensive.
Immuno-oncology assays are designed to measure and interpret immune responses
and tumor characteristics, which requires a deep understanding of immunology
and oncology. This complexity necessitates substantial investment in research
and development (R&D) to create assays that are both accurate and reliable.
The development process typically includes several
stages: initial research, assay design, prototype testing, and optimization.
Each stage requires specialized equipment, skilled personnel, and extensive
experimentation. For instance, designing assays to detect specific biomarkers
or immune cell types involves sophisticated technology and methods such as flow
cytometry, ELISA (enzyme-linked immunosorbent assay), and multiplex assays.
These technologies are costly to acquire and maintain, adding to the overall
development expenses.
Once an assay is developed, it must undergo
rigorous validation to ensure its accuracy, reliability, and clinical utility.
Validation involves conducting extensive preclinical and clinical trials, which
are both time-consuming and expensive. These trials are essential for demonstrating
that the assay performs consistently and provides clinically relevant
information.
Validation costs can be particularly high due to
the need for large patient cohorts and the complexity of conducting studies
that meet regulatory standards. For example, clinical trials must be designed
to evaluate the assay’s performance in real-world settings, including its
ability to predict treatment outcomes and guide clinical decisions. Ensuring
that these trials meet regulatory requirements, such as those set by the FDA
(U.S. Food and Drug Administration) or EMA (European Medicines Agency), further
adds to the costs.
The high development and validation costs of
immuno-oncology assays pose significant financial challenges for companies
operating in this market. Smaller companies and startups, in particular, may
struggle to secure the necessary funding to bring their products to market.
This financial barrier can limit innovation and slow the introduction of new
and potentially groundbreaking assays.
Moreover, the high costs can affect the pricing and
accessibility of assays once they are available. Companies may need to set
higher prices to recoup their R&D investments, which can limit the adoption
of these assays in clinical practice. This can have broader implications for
patient care, as cost constraints may restrict access to advanced diagnostic
tools that are crucial for personalized cancer treatment.
Addressing the challenge of high development and
validation costs requires a multi-pronged approach. Collaboration between
industry stakeholders, including research institutions, healthcare providers,
and funding agencies, can help share the financial burden and accelerate the
development process. Public-private partnerships and grants can also provide
essential funding and support for R&D efforts.
Additionally, leveraging technological advancements
such as high-throughput screening and computational modeling can streamline the
development process and reduce costs. Innovations in assay design and
production techniques can further enhance efficiency and cost-effectiveness.
Key Market Trends
Growing Adoption of Liquid Biopsies
The global immuno-oncology assays market is
witnessing transformative growth, driven by several emerging trends that are
reshaping cancer diagnostics and treatment. Among these, the growing adoption
of liquid biopsies stands out as a pivotal development. Liquid biopsies, which
involve the analysis of circulating tumor DNA (ctDNA), circulating tumor cells
(CTCs), and other biomarkers in blood samples, are revolutionizing the
landscape of cancer diagnostics and monitoring.
Liquid biopsies offer a non-invasive alternative to
traditional tissue biopsies, providing a more accessible and less traumatic
method for cancer diagnosis and monitoring. By analyzing blood samples, these
assays enable the detection of tumor-related biomarkers and genetic mutations
associated with cancer. This approach enhances diagnostic precision, allowing
for the early detection of tumors, monitoring of disease progression, and assessment
of treatment efficacy. As a result, liquid biopsies are becoming an integral
component of immuno-oncology assays, driving demand for advanced testing
solutions that improve patient outcomes.
One of the significant advantages of liquid
biopsies is their ability to provide real-time insights into tumor dynamics and
treatment responses. Unlike traditional biopsies, which may require invasive
procedures and are often limited to specific time points, liquid biopsies offer
continuous monitoring of tumor-related changes through regular blood draws.
This real-time assessment enables oncologists to track how tumors respond to
immunotherapy treatments, make timely adjustments to treatment plans, and
tailor therapies to individual patient needs. The ability to monitor disease
evolution and treatment response in real-time enhances the overall
effectiveness of immuno-oncology therapies.
The shift towards personalized medicine is a
central trend in oncology, and liquid biopsies play a crucial role in this
evolution. By analyzing ctDNA and CTCs, liquid biopsies provide valuable
information about the genetic and molecular characteristics of tumors, enabling
the identification of specific biomarkers that can guide personalized treatment
strategies. This targeted approach ensures that patients receive therapies
tailored to their unique cancer profiles, improving treatment efficacy and
minimizing adverse effects. The integration of liquid biopsies into
immuno-oncology assays supports the broader trend of precision medicine,
driving market growth and innovation.
Traditional tissue biopsies, while valuable, have
limitations such as invasiveness, risk of complications, and the need for
repeated procedures. Liquid biopsies address these limitations by offering a
less invasive alternative that can be performed more frequently. This advantage
is particularly important for patients with difficult-to-access tumors or those
requiring regular monitoring. As the adoption of liquid biopsies grows, it
complements traditional biopsy methods and enhances the overall diagnostic and
monitoring capabilities of immuno-oncology assays.
The increasing adoption of liquid biopsies is
creating new market opportunities within the immuno-oncology assays sector. As
the technology advances and becomes more widely available, the demand for
liquid biopsy tests is expected to rise. This growth presents opportunities for
companies specializing in assay development, technology platforms, and related
services. Investments in research and development, partnerships, and
collaborations will drive innovation and expand the range of liquid biopsy
applications, further fueling market growth.
Regulatory support and clinical advancements are
also contributing to the growing adoption of liquid biopsies. Regulatory
agencies are providing guidelines and frameworks for the approval and use of
liquid biopsy assays, facilitating their integration into clinical practice.
Clinical trials and studies are continuously validating the effectiveness and
utility of liquid biopsies, reinforcing their role in cancer management. As
regulatory and clinical landscapes evolve, the adoption of liquid biopsies is
expected to gain momentum, enhancing the global immuno-oncology assays market.
Segmental Insights
Indication Insights
Based on Indication, Colorectal Cancer have emerged
as the fastest growing segment in the Global Immuno Oncology Assays Market in
2023. Colorectal cancer (CRC) is a major contributor to the global cancer
burden, and its rising incidence is significantly influencing the global
immuno-oncology assays market. The increasing prevalence of colorectal cancer
is driving demand for advanced diagnostic and therapeutic tools, including
immuno-oncology assays, which are essential for the development and
optimization of immunotherapies.
The incidence of colorectal cancer varies across
regions, with higher rates observed in developed countries. In the United
States and Europe, colorectal cancer is among the most prevalent cancers,
largely due to lifestyle factors such as diet, sedentary behavior, and obesity.
However, rising awareness and screening programs are also identifying more
cases in regions with traditionally lower incidence rates, further contributing
to the global burden.
The growing incidence of colorectal cancer is
driving the demand for advanced diagnostic tools, including immuno-oncology
assays. These assays are crucial for identifying specific biomarkers associated
with colorectal cancer and assessing the immune system's response to treatment.
Biomarkers such as microsatellite instability (MSI) and programmed cell death
ligand-1 (PD-L1) expression are key indicators used to tailor immunotherapy
treatments and monitor patient responses.
Immunotherapy has emerged as a promising treatment
modality for colorectal cancer, particularly for patients with mismatch
repair-deficient (dMMR) tumors or MSI-high (MSI-H) status. These tumors are
more likely to respond to immune checkpoint inhibitors, such as PD-1/PD-L1
inhibitors. Immuno-oncology assays play a vital role in identifying patients
who are likely to benefit from these therapies and in guiding treatment
decisions. The increasing use of immunotherapies for colorectal cancer is
driving demand for assays that can accurately assess biomarkers and predict
treatment outcomes.
Technological advancements in immuno-oncology
assays are enhancing the ability to analyze complex tumor and immune system
interactions. Innovations such as next-generation sequencing (NGS), multiplex
assays, and high-throughput screening are improving the accuracy and efficiency
of colorectal cancer diagnostics. These technologies enable comprehensive
genomic profiling and the simultaneous measurement of multiple biomarkers,
supporting the development of more targeted and effective immunotherapies.
Technology Insights
Based on Technology, Polymerase chain reaction
(PCR) have emerged as the dominating segment in the Global Immuno Oncology
Assays Market during the forecast period. Polymerase Chain Reaction (PCR)
technology has become a cornerstone in the global immuno-oncology assays
market, playing a dominant role due to its versatility, precision, and critical
applications in cancer diagnostics and treatment.
PCR is renowned for its high sensitivity and
specificity in detecting specific genetic sequences. In immuno-oncology, this
precision is crucial for identifying cancer-related biomarkers and mutations
that are critical for diagnosis, prognosis, and treatment decisions. PCR assays
can detect low-abundance biomarkers that other methods might miss, providing
detailed insights into tumor genetics and patient responses to therapies.
PCR technology is highly versatile and can be
adapted for various applications in immuno-oncology. It is used for detecting
tumor mutations, identifying pathogen-associated sequences, and assessing gene
expression profiles. This flexibility makes PCR an essential tool for a wide
range of assays, including those for personalized cancer treatment, biomarker
identification, and monitoring therapeutic responses.
PCR offers a rapid turnaround time compared to
traditional methods. The process of amplifying DNA and obtaining results can be
completed within hours, which is critical for timely decision-making in cancer
treatment. Fast results enable clinicians to quickly assess patient conditions
and adapt treatment plans accordingly, enhancing the overall efficiency of
cancer care.
PCR technology is often used in conjunction with
next-generation sequencing (NGS) to provide comprehensive genetic profiling of
tumors. PCR can target specific regions of interest, which are then sequenced
for detailed genetic analysis. This integration allows for high-throughput,
detailed examination of cancer genomes, supporting advanced research and
clinical applications.
PCR is cost-effective compared to some other
advanced diagnostic techniques. Its established protocols and widespread
availability of reagents and equipment make it a practical choice for many
laboratories and clinical settings. The cost-effectiveness of PCR contributes
to its widespread adoption and use in routine cancer diagnostics and research.
The PCR technique has been extensively validated
and standardized, ensuring reproducibility of results across different
laboratories. This consistency is essential for reliable diagnostics and
therapeutic monitoring, and it enhances the credibility of PCR-based assays in
clinical practice.
PCR plays a crucial role in developing companion
diagnostics that are used alongside targeted therapies. By identifying specific
genetic mutations or biomarkers, PCR-based assays help determine patient
eligibility for targeted treatments, ensuring that patients receive the most
effective therapies based on their genetic profiles.
Continuous advancements in PCR technology, such as
real-time PCR (qPCR) and digital PCR (dPCR), have further enhanced its
capabilities. These innovations provide even greater sensitivity,
quantification, and precision, making PCR an increasingly powerful tool in the
evolving landscape of immuno-oncology.
Download Free Sample Report
Regional Insights
Based on Region, North America have emerged as the dominating
region in the Global Immuno Oncology Assays Market in 2023. One of the primary
reasons for North America's dominance in the immuno-oncology assays market is
its highly developed healthcare infrastructure. The region boasts some of the
world's most advanced medical facilities, research centers, and universities,
which are integral to the development and application of cutting-edge
immuno-oncology assays. Institutions such as the National Cancer Institute
(NCI), Memorial Sloan Kettering Cancer Center, and MD Anderson Cancer Center
are at the forefront of cancer research and play a crucial role in advancing
diagnostic and therapeutic technologies.
This infrastructure supports the integration of
innovative assays into clinical practice, facilitating early diagnosis and
personalized treatment approaches. The availability of state-of-the-art
laboratories and skilled professionals ensures that North American facilities
are well-equipped to conduct the complex testing and validation required for
immuno-oncology assays.
North America leads in investment in research and
development (R&D) for immuno-oncology assays. Both public and private
sectors are heavily invested in advancing cancer research and developing new
diagnostic tools. Government funding, such as grants from the National
Institutes of Health (NIH) and the Cancer Research UK, as well as substantial
investments from pharmaceutical and biotechnology companies, contribute to this
robust R&D environment.
This financial support enables the development of
innovative assays and technologies that drive market growth. Additionally, the
presence of numerous biotechnology firms and startups in North America
accelerates the pace of innovation and commercialization, further solidifying
the region’s market leadership.
The regulatory environment in North America,
particularly in the United States, is a significant factor in the region's
dominance. The FDA (U.S. Food and Drug Administration) provides a clear and
structured pathway for the approval of new assays, which, while stringent,
offers a well-defined process for market entry. This regulatory clarity fosters
confidence among developers and investors, encouraging the development and
adoption of new immuno-oncology assays.
Additionally, the FDA’s efforts to expedite the
approval of breakthrough technologies and its initiatives to support
personalized medicine play a critical role in facilitating market growth. The
regulatory framework in Canada also supports the development and approval of
advanced diagnostics, contributing to the overall market strength in North
America.
North America faces a high prevalence of cancer,
which drives the demand for advanced diagnostic tools and therapies. The
region’s large patient population and increasing cancer incidence rates create
a significant market for immuno-oncology assays. This demand drives investment
in developing new assays and integrating them into clinical practice to improve
patient outcomes.
Moreover, the region’s focus on personalized
medicine and precision oncology aligns with the capabilities of immuno-oncology
assays, which are designed to tailor treatments based on individual immune
responses and tumor profiles.
North America’s dominance is also attributable to
its role as a leader in market innovation. The region hosts many of the world’s
leading biotechnology and pharmaceutical companies, which are at the forefront
of developing and commercializing new immuno-oncology assays. This leadership
not only drives technological advancements but also influences global market
trends and standards.
Recent Development
- In July 2024, Tempus AI, Inc., a leader in
artificial intelligence and precision medicine, announced the availability of
its multimodal immune profile score (IPS) algorithmic test for research use
only (RUO). The IPS is the inaugural product in Tempus's expanding
immunotherapy-based portfolio, which aims to introduce next-generation
algorithmic diagnostics to the immuno-oncology field. Additionally, Tempus is
collaborating with partners such as Cleveland Clinic to enhance this portfolio
with more immunotherapy-focused algorithmic tests. These efforts leverage
clinical, laboratory, genomic, and transcriptomic data to identify patients who
may benefit from immunotherapy.
- In February 2024, researchers at UF Health Cancer
Center introduced a groundbreaking compound that may pave the way for new
immunotherapy treatments for various cancers. Laboratory and mouse studies
using skin and colorectal cancer models demonstrated that this compound
significantly slowed the growth of established tumors by harnessing the body's
immune system to target and destroy cancer cells. In some cases, the compound
even led to the complete eradication of the tumors.
- In February 2023, Agilent Technologies announced
the integration of its xCelligence RTCA HT (real-time cell analysis
high-throughput) platform with the BioTek BioSpa 8 Automated Incubator. This
integration enhances workflow automation by combining these technologies.
According to Agilent, this development responds to market demands by offering
new capabilities for creating label-free high-throughput potency assays in the
immuno-oncology field and high-throughput viral cytopathic effects (CPE) assays
for the vaccine market.
Key Market Players
- Agilent Technologies, Inc.
- BIO-RAD
LABORATORIES, INC.
- Charles
River Laboratories, Inc.
- F.
Hoffmann-La Roche Ltd
- Illumina,
Inc.
- NanoString
Technologies, Inc.
- PerkinElmer
Inc.
- QIAGEN
N.V.
- Sartorius
AG
- THERMO
FISHER SCIENTIFIC, INC.
|
By
Indication
|
By Technology
|
By Region
|
- Colorectal
Cancer
- Lung Cancer
- Melanoma
Cancer
- Bladder
Cancer
- Others
|
- Immunoassays
- Polymerase
chain reaction (PCR)
- Next-generation
sequencing (NGS)
- Flow
Cytometry
|
- North
America
- Europe
- Asia Pacific
- South
America
- Middle East
& Africa
|
Report Scope:
In this report, the Global Immuno Oncology Assays
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Immuno Oncology Assays Market, By Indication:
o Colorectal Cancer
o Lung Cancer
o Melanoma Cancer
o Bladder Cancer
o Others
- Immuno Oncology Assays Market, By Technology:
o Immunoassays
o Polymerase chain reaction (PCR)
o Next-generation sequencing (NGS)
o Flow Cytometry
- Immuno Oncology Assays Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Immuno
Oncology Assays Market.
Available Customizations:
Global Immuno Oncology Assays Market report with
the given market data, Tech Sci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Immuno Oncology Assays Market is an upcoming
report to be released soon. If you wish an early delivery of this report or
want to confirm the date of release, please contact us at [email protected]